Zobrazeno 71 - 80
of 1 548
pro vyhledávání: ''
Autor:
Jason F. Kreisberg, Justin K. Huang, Sean Tang, Trey Ideker, John Paul Shen, Kyle S. Sanchez, Katherine Licon, Alex Beckett, Wei Zhang, Tina Wang, Ana Bojorquez-Gomez, Nam Bui
Publikováno v:
Molecular Cancer Therapeutics. 17:1585-1594
Human papillomavirus (HPV)–negative head and neck squamous cell carcinoma (HNSCC) represents a distinct classification of cancer with worse expected outcomes. Of the 11 genes recurrently mutated in HNSCC, we identify a singular and substantial surv
Autor:
Gregory J. Riely, Marc Ladanyi, Ryan Kim, Ken Suzawa, Matthew D. Hellmann, Helena A. Yu, Maria E. Arcila, Ahmet Zehir, Ai Ni, Bob T. Li, Michael F. Berger, Romel Somwar, Emmet Jordan, Mark G. Kris, David B. Solit
Publikováno v:
Clinical Cancer Research. 24:3108-3118
Purpose: To identify molecular factors that determine duration of response to EGFR tyrosine kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly profiled EGFR-mutant tumors prior to treatment and after progression on
Autor:
Isaac K. Nardi, Dan J. Raz, Lu Yang, Jinhui Wang, Jami Wang, Rajendra P. Pangeni, Xinwei Yun, Melissa Bonner, Ming Gao, Keqiang Zhang, Jun Wu
Publikováno v:
Molecular Cancer Research. 16:1161-1171
Loss of monoubiquitination of histone H2B (H2Bub1) was found to be associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. This study investigated the association and impact of the ubiquitin-specific peptidase 22 (USP22),
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Autor:
Tobias Herold, Luise Hartmann, Wolfgang Hiddemann, Philipp A. Greif, Daniela Schumacher, Bianka Ksienzyk, Claudia D. Baldus, Bernhard Wörmann, Evelyn Zellmeier, Stephan Wolf, Sebastian Vosberg, Friederike Pastore, Helmut Blum, Stephanie Schneider, Sophie M. Stief, Stefanos A. Bamopoulos, Wolfgang E. Berdel, Ines Hellmann, Stefan Krebs, Alexander Graf, Karsten Spiekermann, Klaus H. Metzeler, Stefan K. Bohlander, Vindi Jurinovic, Nikola P. Konstandin, Raphael Mattes, Dennis Görlich, Martin Neumann, Kathrin Bräundl, Paul Kerbs
Publikováno v:
Clinical Cancer Research. 24:1716-1726
Purpose: To study mechanisms of therapy resistance and disease progression, we analyzed the evolution of cytogenetically normal acute myeloid leukemia (CN-AML) based on somatic alterations. Experimental Design: We performed exome sequencing of matche
Autor:
Gregory Sliwoski, Jie He, Jens Meiler, Daniel J. Zabransky, Dan Ye, Ariella B. Hanker, CL Arteaga, Vincent A. Miller, Sarah Croessmann, James P. Koch, Lisa N. Kinch, Alshad S. Lalani, Richard E. Cutler, M Red Brewer, Jonathan H. Sheehan
Publikováno v:
Cancer Research. 79:PD3-05
ERBB2, the gene encoding HER2, is mutated in 2-4% of breast cancers. The HER2 tyrosine kinase inhibitor neratinib has shown clinical activity against breast cancers harboring HER2 activating mutations, suggesting these tumors depend on HER2 signaling
Autor:
Jamie J. Shah, Francis Y. Lee, Bruce S. Fischer, Hossein Khiabanian, Sharon R. Pine, Joseph R. Bertino, Katherine M. Morgan, Amartya Singh, Jeffrey A. Rosenfeld
Publikováno v:
Molecular Cancer Therapeutics. 16:2759-2769
Notch signaling is aberrantly activated in approximately one third of non–small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in pr
Autor:
Jill Hallin, Lyudmilla Bazhenova, James G. Christensen, Natalia Baños, Richard C. Chao, Camino Menéndez, Mark M. Awad, Nir Peled, Mizuki Nishino, Peter Olson, V. Tassell, Richard B. Lanman, Geoffrey I. Shapiro, Matthew Randolf Lee, Lars D. Engstrom, Zachary Madaj, Sandip Pravin Patel, Manuel Hidalgo, Ruth Aranda, Carrie R. Graveel, Pasi A. Jänne, David Briere, Elizabeth A. Tovar, Curt J. Essenburg, Harrah Chiang, Pedro P. López-Casas, Darya Chudova
Publikováno v:
Clinical Cancer Research. 23:6661-6672
Purpose: MET exon 14 deletion (METex14 del) mutations represent a novel class of non–small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a spectrum-selective MET inhibitor exhibiting a type II binding mode, in METex14 del–po
Autor:
Daniela Meco, Nadia Trivieri, Anna Lasorella, Valentina Muto, Maurizio Martini, Marco Tartaglia, Matteo Lucchini, Alessandro Bruselles, Andrea Ciolfi, Massimo Caldarelli, Massimiliano Mirabella, Tiziana Servidei, Riccardo Riccardi, Roberta Morosetti
Publikováno v:
Cancer Research. 77:5860-5872
The basis for molecular and cellular heterogeneity in ependymomas of the central nervous system is not understood. This study suggests a basis for this phenomenon in the selection for mitogen-independent (MI) stem-like cells with impaired proliferati
Autor:
Amit Aggarwal, Gregory P. Donoho, Gregory D. Plowman, Ramon V. Tiu, Robert D. Van Horn, Sheng Bin Peng, Youyan Zhang, Jason C. Ting, Ruslan D. Novosiadly, Yue Webster, Yung Mae M. Yao, Amelie Forest, Philip W. Iversen, Henry James Robert, Philip J. Ebert, Steven M. Bray
Publikováno v:
Clinical Cancer Research. 23:5547-5560
Purpose: To evaluate the antitumor efficacy of cetuximab in combination with LSN3074753, an analog of LY3009120 and pan-RAF inhibitor in 79 colorectal cancer patient-derived xenograft (PDX) models. Experimental Design: Seventy-nine well-characterized